key: cord-0948712-vyl6040l
authors: DiPiazza, Anthony T.; Graham, Barney S.; Ruckwardt, Tracy J.
title: T cell immunity to SARS-CoV-2 following natural infection and vaccination
date: 2020-10-23
journal: Biochem Biophys Res Commun
DOI: 10.1016/j.bbrc.2020.10.060
sha: db1b999b0583a4d5ae614d8e508a8f02bd59acb8
doc_id: 948712
cord_uid: vyl6040l

SARS-CoV-2 first emerged in the human population in late 2019 in Wuhan, China, and in a matter of months, spread across the globe resulting in the Coronavirus Disease 19 (COVID-19) pandemic and substantial economic fallout. SARS-CoV-2 is transmitted between humans via respiratory particles, with infection presenting a spectrum of clinical manifestations ranging from asymptomatic to respiratory failure with multiorgan dysfunction and death in severe cases. Prior experiences with human pathogenic coronaviruses and respiratory virus diseases in general have revealed an important role for cellular immunity in limiting disease severity. Here, we review some of the key mechanisms underlying cell-mediated immunity to respiratory viruses and summarize our current understanding of the functional capacity and role of SARS-CoV-2-specific T cells following natural infection and vaccination.

Additionally, production of IFN-γ, TNF-α, GzmB and/or surface expression of the CD107a marker of 188 degranulation has been detected in CD8 + T cells [31, 43] surface protein relative to nucleoprotein [73] . Links between antigen specificity and effector function of 

Abundance and specificity of influenza reactive 604 circulating memory follicular helper and non-follicular helper CD4 T cells in healthy adults

T follicular regulatory cells in mice and 607 men

Recurrent group A Streptococcus 611 tonsillitis is an immunosusceptibility disease involving antibody deficiency and aberrant TFH cells

Massachusetts Consortium on Pathogen Readiness Specimen Working, Loss 620 of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19

SARS-CoV-2 vaccines in development

Clinical and immunological 625 assessment of asymptomatic SARS-CoV-2 infections

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in 655 Nonhuman Primates

An mRNA Vaccine 661 against SARS-CoV-2 -Preliminary Report

Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults

Concurrent human antibody and Th1 type T-cell responses elicited by a COVID-673 19 RNA vaccine, medRxiv

RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study

CoV-2 in rhesus macaques

Safety and immunogenicity of an rAd26 and rAd5 vector-705 based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised 706 phase 1/2 studies from Russia

Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein 711

Nanoparticle Vaccine

) All third-party financial support for the work in the submitted manuscript

All sources of revenue with relevance to the submitted work who made payments to you, or to your institution on your behalf

Any other interactions with the sponsor of outside of the submitted work should also be reported. (5) Any relevant patents or copyrights (planned, pending, or issued)

Any other relationships or affiliations that may be perceived by readers to have influenced, or give the appearance of potentially influencing, what you wrote in the submitted work. As a general guideline